Castle biosciences inc.

Who can I contact if I have a question? Please call our customer service staff at 866-788-9007 or email [email protected]. Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes.Jun 23, 2019 · Our History. Castle Biosciences was founded by Derek Maetzold who believed that traditional methods to determine cancer patients’ prognosis could be improved by newly emerging techniques in molecular biology. We continue to focus on transforming disease management in areas of unmet clinical need through the development and marketing of ... Castle Biosciences (CSTL-0.50%) stock was absolutely crushing it on Friday, with shares skyrocketing 54.4% as of 11:47 a.m. ET. The huge gain came after Novitas, a regional Medicare administrative ...Castle Biosciences to acquire mental health testing co. AltheaDX in deal worth up to $140M. Friendswood-based diagnostics company Castle Biosciences Inc. (Nasdaq: CSTL) will acquire San Diego ...19 Feb 2022 ... Castle Biosciences, Inc., Friendswood, TX 77546, USA. 7 Department of Dermatology, University of Barcelona, IDIBAPS, 08007 Barcelona, Spain ...

Castle Biosciences is a high growth, commercial stage molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about their treatment and ...Castle’s three-year financial targets include anticipated total revenue of $255-$330 million and anticipated net operating cash flow positivity for the year ending December 31, 202512 hours ago · Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx-Melanoma in patients diagnosed with cutaneous melanoma.

Castle Biosciences, Inc. | 10,098 followers on LinkedIn. Improving health through innovative tests that guide patient care | Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company... Belgium, a country known for its rich history, stunning architecture, and vibrant culture, offers a plethora of attractions for visitors to explore. From medieval castles to modern art galleries, Belgium has something for everyone.

According to the issued ratings of 4 analysts in the last year, the consensus rating for Castle Biosciences stock is Buy based on the current 4 buy ratings for CSTL. The average twelve-month price prediction for Castle Biosciences is $32.29 with a high price target of $41.00 and a low price target of $25.00. Learn more on CSTL's analyst rating ...Nov 2, 2023 · Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating the personalized information our tests provide. According to the issued ratings of 4 analysts in the last year, the consensus rating for Castle Biosciences stock is Buy based on the current 4 buy ratings for CSTL. The average twelve-month price prediction for Castle Biosciences is $32.29 with a high price target of $41.00 and a low price target of $25.00. Learn more on CSTL's analyst rating ... Aug 2, 2023 · CASTLE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (in thousands) Six Months Ended. June 30, 2023 2022 OPERATING ACTIVITIES Net loss $ (47,981 ) $ ...

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. (AltheaDx). AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx) testing services that ...

Castle Biosciences, Inc. believes this leads to better treatment plan decisions, optimized health outcomes and reduced healthcare costs when compared to traditional clinical and pathologic features.

Castle Biosciences works with all insurance providers, including Medicare, Medicaid, commercial insurers, and the VA to secure coverage and payment for the DecisionDx-Melanoma test. Castle will submit insurance claims and manage the insurance billing process on behalf of patients. The company also sponsors an industry-leading Patient …National award recognizes Castle’s strong culture and employee engagement. September 19, 2023 07:00 AM Eastern Daylight Time. FRIENDSWOOD, Texas-- ( BUSINESS WIRE )--Castle Biosciences, Inc ...Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.What happened. Castle Biosciences ( CSTL -0.50%) stock was absolutely crushing it on Friday, with shares skyrocketing 54.4% as of 11:47 a.m. ET. The huge gain came after Novitas, a regional ...Currently, John Abbott is Vice President & Controller at Castle Biosciences, Inc. He received an undergraduate degree and a graduate degree from Texas A&M University. Current positions of John Abbott : Name: Title: Since: Castle Biosciences, Inc. (Medical Equipment, Supplies & Distribution) Vice President & Controller:

Founder, President and CEO. Derek J. Maetzold founded Castle Biosciences in September 2007 and has served as our President, Chief Executive Officer and as a member of our board of directors since inception. Previously, Mr. Maetzold held leadership roles at Encysive Pharmaceuticals, Schering-Plough Corporation (now Merck), Integrated ... Castle Biosciences, Inc. | 10,098 followers on LinkedIn. Improving health through innovative tests that guide patient care | Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company... Nov 23, 2023 · Castle Biosciences Inc’s trailing 12-month revenue is $192.0 million with a -39.3% profit margin. Year-over-year quarterly sales growth most recently was 66.2%. Analysts expect adjusted earnings to reach $-2.723 per share for the current fiscal year. Castle Biosciences Inc does not currently pay a dividend. C/O CASTLE BIOSCIENCES, INC. 505 S. FRIENDSWOOD DRIVE, SUITE 401 (Street) FRIENDSWOOD: TX: 77546 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol CASTLE BIOSCIENCES INC [ CSTL] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X: Director:Invisible Fence Inc. is a leading provider of innovative pet containment and lifestyle solutions. With over 40 years of experience, Invisible Fence Inc. has developed products that are designed to keep pets safe and secure in their own yard...Nov 4, 2023 · Castle Biosciences, Inc. 19.85. +0.47. +2.43%. Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Good afternoon and welcome to Castle Biosciences ...

Castle Biosciences is a commercial-stage dermatological cancer company focused on providing physicians and their patients with personalized, clinically ...

For your first test order, please call us at 866-788-9007. You will be given instructions on filling out the requisition form, as well as the details of our testing, processing, and reporting procedures. Turnaround time for a report from our CLIA-certified, CAP-accredited laboratory is typically within 2 to 3 weeks of receiving the specimen.Nov 14, 2023 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago. Castle Biosciences, Inc. 19.85. +0.47. +2.43%. Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Good afternoon and welcome to Castle Biosciences ...Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET. Company Participants. Camilla Zuckero - Vice President, Investor Relations and Corporate Affairs.May 2018 - Present5 years 6 months. Baltimore, Maryland Area. 2019 Circle of Excellence Award Winner (178% to goal) 2021- 134.1% to goal. New business development of Castle Biosciences Cancer ...Deciding the frequency and intensity of follow-up and surveillance. DecisionDx-SCC is performed on formalin-fixed, paraffin embedded (FFPE) primary tumor tissue from either a biopsy or excision. Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes. Castle Biosciences Named a Winner of the 2023 Top Workplaces USA Award for the Second Year! Castle Biosciences Inc. is growing, and we are looking to hire a Pre-Billing Prior Authorization ...

Nov 2, 2023 · Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended September ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has completed its ...

Cutaneous Squamous Cell Carcinoma. Cutaneous squamous cell carcinoma (SCC), non-melanoma skin cancer, is one of the most common cancers with an estimated incidence of more than 1,000,000 cases in the U.S. each year. Approximately 20% of patients have high-risk factors based on tumor depth, histology, anatomic location, and/or immunosuppression.7 Jul 2023 ... ... Castle Biosciences Slumped This Week. featured-transcript-logo. Castle Biosciences, Inc. (CSTL) Q3 2019 Earnings Call Transcript. 524%. Premium ...Jun 2, 2023 · Shares of Castle Biosciences ( CSTL 0.15%) closed this week down 12.6% for the week, after being down as much as 18.3% for the week, according to data provided by S&P Global Market Intelligence ... On June 6, 2022, the Reporting Person transferred 130,000 shares of Castle Biosciences, Inc. common stock that was previously not reported to the DJM Grantor Retained Annuity Trust No. 4 of which the Reporting Person is trustee and beneficiary. 4. Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse …An experienced team with deep expertise in discovering, developing, and commercializing diagnostic and prognostic tests. Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.Castle Biosciences, Inc. | 10,098 followers on LinkedIn. Improving health through innovative tests that guide patient care | Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company...Castle Creek Biosciences, Inc. Biotechnology Research Exton, Pennsylvania Timber Pharmaceuticals, Inc. Pharmaceutical Manufacturing ...Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. A Focus on Transforming Disease Management. Our approach to product development starts by identifying areas of unmet medical need where precision medicine could significantly improve disease staging and/or patient care decisions. We focus first on confirming the clinical challenges of these unmet needs and look for opportunities where current ...Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Castle Biosciences, Inc. Stock Symbol NASDAQ:CSTL. Company Type For Profit. Contact Email [email protected]. Phone Number 602-535-1997. Castle Biosciences is a biotech company that develops and validates diagnostic tests and technologies for the treatment of cancer.

Shares of Castle Biosciences ( CSTL 0.15%) closed this week down 12.6% for the week, after being down as much as 18.3% for the week, according to data provided by S&P Global Market Intelligence ...On April 12, 2023, Castle Biosciences, Inc. (“Castle”) filed a definitive proxy statement (the “Proxy Statement”) with the Securities and Exchange Commission in connection with its 2023 Annual Meeting of Stockholders to be held on May 25, 2023 (the “Annual Meeting”). On May 15, 2023, Castle issued the below letter to its stockholders.Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.25 per share a year ago.Instagram:https://instagram. how much is a gold coin worthbest altcoin exchangeschannel stockuncirculated coins vs circulated White Castle restaurants have operated in the United States for almost 100 years. That’s amazing enough, but the biggest shocker is that the more than 375 fast food restaurants are still completely under the company’s control. That feat is ... binary forexone dollar liberty coin 1979 Apr 4, 2022 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. (AltheaDx). AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx) testing services that ... private reit funds Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to ...Castle Biosciences, Inc., Friendswood, Texas. 629 likes · 38 talking about this. Leading diagnostics company improving health through innovative tests...Castle Creek Biosciences, Inc. Biotechnology Research Exton, Pennsylvania Timber Pharmaceuticals, Inc. Pharmaceutical Manufacturing ...